Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 37 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
APR Pharma from Courcelles, company number BE0748905227, closed financial year 2025 with a result of € 39,279 after tax. For that financial year APR Pharma recorded a gross margin of € 70,657 and equity of € 93,506. Compared with financial year 2024, the result moved from € -28,220 to € 39,279. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 19, 2026.
€ 93,506
▲ € 89,279 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 39,279
▲ still € 28,220 loss in 2024
Profit after tax over the fiscal year.
€ 46,448
▼ 29% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 38,506.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 16,432
▼ 86% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -172,247 | € -2,511 | € -667 | € 70,657 | ▲ € 71,325 |
| Profit after taxes | € -197,624 | € -27,926 | € -28,220 | € 39,279 | ▲ € 67,499 |
| Equity | € 60,373 | € 32,447 | € 4,227 | € 93,506 | ▲ € 89,279 |
| Total debts | € 249,407 | € 206,721 | € 258,836 | € 151,449 | ▼ 41% |
| Cash | € 100,466 | € 29,276 | € 65,020 | € 46,448 | ▼ 29% |
| Retained profit | € -439,627 | € -467,553 | € -495,773 | € 38,506 | ▲ € 534,279 |
| Balance sheet total | € 309,780 | € 239,168 | € 263,063 | € 244,955 | ▼ 7% |
Key figures of APR Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to APR Pharma?
What happened at APR Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 39,279. filed late Source: NBB ↗
- New establishment in Courcelles. KBO
- Start of the company according to the CBE. KBO
- Joris Pieter De Gussem became a director. NBB
- RXW GROUP SA became a director. NBB
- CONSOLID SRL became a director. NBB
- Maarten De Gussem became a director. NBB
In short
From € 197,624 loss in 2022 to € 39,279 profit in 2025.
Best year ever: 2025, with € 39,279 profit.
A new publication or filing at APR Pharma? We notify you, reason included.
Follow APR PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of CONSOLID comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
APR PharmaBehind APR Pharma are Joris Pieter De Gussem, RXW GROUP SA, CONSOLID SRL and Maarten De Gussem. The shares are held by CONSOLID (10%).
Directors
According to the 2025 annual accounts
Managing director · represented by Christiaan Willaert
Also active at: EYTELIA, CFG Pharma
since 2020
Director · represented by Dries Moens
Also active at: CUBX Properties, RXW Group, ACTIVIOR, PremiumStock, DMD Real Estate, Advantage Real Estate, RLST, FINVET +4 more
since 2020
Shareholders
10%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue de Liège(CO) 2
6180 Courcelles
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0748.905.227
- VAT number
- BE 0748.905.227
- Registered office
- Rue de Liège(CO) 2, 6180 Courcelles
- Names & denominations
- APR Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 June 2020
- Peppol
- Active · Active since 24 Feb 2026
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Groothandel in farmaceutische en medische artikelen
Vervaardiging van geneesmiddelen
Groothandel in andere voedingsmiddelen, neg
Overige zakelijke dienstverlening, neg
Activiteiten van holdings
Speur- en ontwikkelingswerk op biotechnologisch gebied
+8